Not currently approved for paediatric use.
The frequency of serious infection among Xeljanz-treated subjects 65 years of age and older was higher than among those younger than age 65.
Safety has not been determined.
Use with caution in the elderly.
Contraindicated in use with pregnancy.
Contraindicated in use with breastfeeding.